Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
18 hedge funds and large institutions have $864K invested in Hepion Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
13% more funds holding
Funds holding: 16 → 18 (+2)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
51% less capital invested
Capital invested by funds: $1.77M → $864K (-$908K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$186K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$21.4K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$15K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.41K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$43.8K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$369 |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$295 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$221 |
| 5 |
AF
Advisornet Financial
Minnetonka,
Minnesota
|
-$148 |
HEPA Hedge Fund Activity: Q2 2024 in Review
18 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2024, worth a combined $864K — down 51% from $1.77M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new HEPA positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, adding an estimated $186K. The largest seller was Vanguard Group, cutting an estimated $43.8K.
- 18 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2024, up from 16 in Q1 2024.
- Funds reported $864K of Hepion Pharmaceuticals stock for Q2 2024, down 51% quarter-over-quarter.
- 3 funds opened new Hepion Pharmaceuticals positions in Q2 2024 and 1 closed out, a net change of +2 holders.
- The largest Hepion Pharmaceuticals buyer in Q2 2024 was Armistice Capital, an estimated $186K added.
- The largest Hepion Pharmaceuticals seller in Q2 2024 was Vanguard Group, an estimated $43.8K sold.
Based on aggregated 13F filings for Q2 2024.